Patents Assigned to Biogaia AB
-
Patent number: 10232001Abstract: The present invention comprises a method for selecting lactic acid bacterial strains effective for preventing bone loss in humans and strains that have been selected according to the presented method. The selection method is based on the strain's capability of reestablishing an altered microbial community to normal and/or harboring at least one of four specific SNPs.Type: GrantFiled: March 12, 2018Date of Patent: March 19, 2019Assignees: BioGaia AB, Board of Trustees of Michigan State UniversityInventors: Eamonn Connolly, Robert Allen Britton, Laura Rae McCabe
-
Patent number: 10174388Abstract: A method is provided for evaluating agents for the treatment of different intestinal motility disorders, using distinct methodological parts related to musculature and nerves of the GI tract which communicate with the brain. In particular, the present invention provides a method for the selection of an agent effective for the treatment of an intestinal motility disorder, wherein the method comprises: a) a step of spatiotemporal (ST) mapping carried out on a gastrointestinal segment to analyze the effect of the agent on gastrointestinal motility; and b) a step of ex vivo nerve bundle recording carried out on a gastrointestinal segment to analyze the effect of the agent on mesenteric afferent nerve firing. Bacterial strains selected by the methods of the invention and the use of the bacterial strains in the treatment of intestinal motility disorders are also provided.Type: GrantFiled: September 15, 2017Date of Patent: January 8, 2019Assignee: BioGaia ABInventors: Eamonn Connolly, Wolfgang Kunze, John Bienenstock
-
Patent number: 10143713Abstract: The present invention generally relates to a strain of Lactobacillus probiotic bacteria and a poultry vaccine for use in the in ovo vaccination of poultry, wherein said strain and said vaccine are administered to an embryonated poultry egg. Compositions suitable for use in an in ovo vaccination protocol for poultry comprising a strain of Lactobacillus probiotic bacteria and a vaccine diluent which is suitable for the poultry vaccine to be used in said vaccination protocol are also provided, as are suitable kits for use in the invention.Type: GrantFiled: June 24, 2015Date of Patent: December 4, 2018Assignee: Biogaia ABInventors: Uma Nathan, Bo Möllstam
-
Patent number: 10143714Abstract: The present invention generally relates to a strain of Lactobacillus probiotic bacteria and a poultry vaccine for use in the in ovo vaccination of poultry, wherein said strain and said vaccine are administered to an embryonated poultry egg. Compositions suitable for use in an in ovo vaccination protocol for poultry comprising a strain of Lactobacillus probiotic bacteria and a vaccine diluent which is suitable for the poultry vaccine to be used in said vaccination protocol are also provided, as are suitable kits for use in the invention.Type: GrantFiled: November 27, 2017Date of Patent: December 4, 2018Assignee: Biogaia ABInventors: Uma Nathan, Bo Möllstam
-
Publication number: 20180200313Abstract: The present invention comprises a method for selecting lactic acid bacterial strains effective for preventing bone loss in humans and strains that have been selected according to the presented method. The selection method is based on the strain's capability of reestablishing an altered microbial community to normal and/or harboring at least one of four specific SNPs.Type: ApplicationFiled: March 12, 2018Publication date: July 19, 2018Applicants: BIOGAIA AB, MICHIGAN STATE UNIVERSITYInventors: Eamonn Connolly, Robert Allen Britton, Laura Rae McCabe
-
Patent number: 10004770Abstract: A method is provided of selecting specific probiotic lactic acid bacteria producing histamine and the use of such strains for beneficial effects for mammals. The method includes selecting a lactic acid bacterial strain for use in the local production of histamine in a mammal, and further comprises screening bacteria for the presence of an active histidine operon and selecting a strain which has an active histidine operon and is capable of producing histamine. Preferably said strain is selected for its ability to produce histamine at a level of greater than 250 pg/ml. The present invention further provides products comprising the strains obtainable by the selection methods of the invention for use in the local production of histamine in a mammal, in particular for use in the treatment or prophylaxis of inflammatory conditions.Type: GrantFiled: October 10, 2016Date of Patent: June 26, 2018Assignee: BIOGAIA ABInventors: James Versalovic, Carissa Michelle Thomas, Eamonn Connolly
-
Patent number: 9968643Abstract: The present invention comprises a method for selecting lactic acid bacterial strains effective for preventing bone loss in humans and strains that have been selected according to the presented method. The selection method is based on the strain's capability of reestablishing an altered microbial community to normal and/or harboring at least one of four specific SNPs.Type: GrantFiled: October 21, 2016Date of Patent: May 15, 2018Assignees: BIOGAIA AB, MICHIGAN STATE UNIVERSITYInventors: Eamonn Connolly, Robert Allen Britton, Laura Rae McCabe
-
Patent number: 9816150Abstract: A method is provided for evaluating agents for the treatment of different intestinal motility disorders, using distinct methodological parts related to musculature and nerves of the GI tract which communicate with the brain. In particular, the present invention provides a method for the selection of an agent effective for the treatment of an intestinal motility disorder, comprising: a) a step of spatiotemporal (ST) mapping carried out on a gastrointestinal segment to analyze the effect of the agent on gastrointestinal motility; and b) a step of ex vivo nerve bundle recording carried out on a gastrointestinal segment to analyze the effect of the agent on mesenteric afferent nerve firing. Bacterial strains selected by the methods of the invention and the use of the bacterial strains in the treatment of intestinal motility disorders are also provided.Type: GrantFiled: December 23, 2016Date of Patent: November 14, 2017Assignee: BioGaia ABInventors: Eamonn Connolly, Wolfgang Kunze, John Bienenstock
-
Publication number: 20170128501Abstract: The present invention comprises a method for selecting lactic acid bacterial strains effective for preventing bone loss in humans and strains that have been selected according to the presented method. The selection method is based on the strain's capability of reestablishing an altered microbial community to normal and/or harboring at least one of four specific SNPs.Type: ApplicationFiled: October 21, 2016Publication date: May 11, 2017Applicants: BIOGAIA AB, Michigan State UniversityInventors: Eamonn Connolly, Robert Allen Britton, Laura Rae McCabe
-
Publication number: 20170095516Abstract: The present invention generally relates to a strain of Lactobacillus probiotic bacteria and a poultry vaccine for use in the in ovo vaccination of poultry, wherein said strain and said vaccine are administered to an embryonated poultry egg. Compositions suitable for use in an in ovo vaccination protocol for poultry comprising a strain of Lactobacillus probiotic bacteria and a vaccine diluent which is suitable for the poultry vaccine to be used in said vaccination protocol are also provided, as are suitable kits for use in the invention.Type: ApplicationFiled: June 24, 2015Publication date: April 6, 2017Applicant: Biogaia ABInventors: Uma Nathan, Bo Möllstam
-
Patent number: 9555065Abstract: A method is provided for evaluating agents for the treatment of different intestinal motility disorders, using distinct methodological parts related to musculature and nerves of the GI tract which communicate with the brain. In particular, the present invention provides a method for the selection of an agent effective for the treatment of an intestinal motility disorder, wherein said method comprises: a) a step of spatiotemporal (ST) mapping carried out on a gastrointestinal segment to analyze the effect of said agent on gastrointestinal motility; and b) a step of ex vivo nerve bundle recording carried out on a gastrointestinal segment to analyze the effect of said agent on mesenteric afferent nerve firing. Bacterial strains selected by the methods of the invention and the use of said bacterial strains in the treatment of intestinal motility disorders are also provided.Type: GrantFiled: September 3, 2013Date of Patent: January 31, 2017Assignee: BioGaia ABInventors: Eamonn Connolly, Wolfgang Kunze, John Bienenstock
-
Publication number: 20160334391Abstract: The present embodiments relate to selection of agents effective in reducing or preventing gastrointestinal pain in a subject. Such an agent is selected and identified if it is capable of reducing spontaneous and/or induced transient receptor potential vanilloid 1 (TRPV1) activation.Type: ApplicationFiled: January 23, 2015Publication date: November 17, 2016Applicant: BIOGAIA ABInventors: Eamonn Conolly, Wolfgang Kunze, John Bienenstock
-
Patent number: 9351512Abstract: A method is provided of prolonging the shelf life of probiotic lactic-acid producing bacteria formulated in oil, by using a specific moisture absorbing technology.Type: GrantFiled: June 11, 2014Date of Patent: May 31, 2016Assignee: Biogaia ABInventor: Elisabeth Sjoberg
-
Patent number: 9340840Abstract: The invention herein provides certain strains of lactic acid bacteria selected for their capability of promoting production of IL-10 and consequently proliferation of CD4+CD25+ TR cells, for prophylaxis and/or treatment of infant colic, a method of selecting such strains, and products containing such strains.Type: GrantFiled: January 23, 2012Date of Patent: May 17, 2016Assignee: Biogaia ABInventors: Eamonn Connolly, Bo Mollstam
-
Patent number: 9057112Abstract: The invention herein provides certain strains of lactic acid bacteria selected for their capability of promoting production of IL-10 and consequently proliferation of CD4+CD25+ TR cells, for prophylaxis and/or treatment of infant colic, a method of selecting such strains, and products containing such strains.Type: GrantFiled: October 29, 2007Date of Patent: June 16, 2015Assignee: BIOGAIA ABInventors: Eamonn Connolly, Bo Mollstam
-
Publication number: 20150150917Abstract: The present invention comprises a method for selecting lactic acid bacterial strains effective for preventing bone loss in humans and strains that have been selected according to the presented method. The selection method is based on the strain's capability of reestablishing an altered microbial community to normal and/or harboring at least one of four specific SNPs.Type: ApplicationFiled: June 4, 2013Publication date: June 4, 2015Applicants: Michigan State University, BIOGAIA ABInventors: Eamonn Connolly, Robert Allen Britton, II, Laura Rae McCabe
-
Patent number: 8945534Abstract: Methods for the controlled activation of the reuterin-production machinery of Lactobacillus reuteri by adding glycerol and other substances during the manufacture of cell-cultures and keeping the produced reuterin in the bacterial cell during preservation and storage. In particular this invention relates to the manufacture of large amounts of L. reuteri that are loaded with reuterin, and the use of such loaded bacteria for applications such as prevention and treatment of diseases, for food applications and the like.Type: GrantFiled: November 4, 2013Date of Patent: February 3, 2015Assignee: BioGaia ABInventor: Stefan Roos
-
Publication number: 20140363409Abstract: The invention relates to Lactobacillus reuteri DSM 17938, and compositions comprising Lactobacillus reuteri DSM 17938, for promoting the healthy development and/or repair of the enteric nervous system in mammals. Humans or animals and, in particular, a foetus, pre-term or term-born infant, toddler or child may benefit from the invention. The invention may be especially beneficial to those infants having experienced IUGR, or having a low, or very low birth weight, and/or suffered from enteric nervous system growth retardation either in utero or, during or after birth. The administration of to Lactobacillus reuteri DSM 17938 promotes normal and healthy neuronal and glial development. It also ensures healthy neuronal differentiation in the peripheral nervous system.Type: ApplicationFiled: November 30, 2012Publication date: December 11, 2014Applicant: BioGaia ABInventors: Gabriela Bergonzelli Degonda, Magali Faure, Nicole Kusy
-
Publication number: 20140363410Abstract: The invention relates to Lactobacillus reuteri DSM 17938 for promoting the establishment of healthy and normal cognitive function in young mammals. In particular, the invention relates to the use of Lactobacillus reuteri DSM 17938 for promoting development of the brain structures responsible for cognitive functions (e.g. cortex and hippocampus) and its associated neural pathways and/or to reverse retardation and/or to prevent retardation of the establishment of cognitive functions. Humans or animals and, in particular, a foetus, pre-term or term born infant, toddler or child or a young adult may benefit from the invention.Type: ApplicationFiled: November 30, 2012Publication date: December 11, 2014Applicant: BioGaia ABInventors: Gabriela Bergonzelli Degonda, Magali Faure, Nicole Kusy
-
Patent number: 8785183Abstract: A method is provided of prolonging the shelf life of probiotic lactic-acid producing bacteria formulated in oil, by using a specific moisture absorbing technology.Type: GrantFiled: September 19, 2011Date of Patent: July 22, 2014Assignee: Biogaia ABInventor: Elisabeth Sjoberg